The following informations are relevant to the Supply Situation of Myozyme. The documents below represent guidance to physicians and patients in light of the current tight supply of Myozyme.
A press release was issued by the European Medicines Agency (EMEA) giving guidance to European healthcare professionals. We would encourage everyone to read the information from the EMEA for detailed information on the Myozyme supply management plan.
EMEA Press Release (Link to EMEA)
EMEA Press Release (PDF, 34 kB)
The below informations are relevant to the global Supply Situation. They have been distributed to all treating physicians worldwide except those in the European Union (EU). Separate guidance was sent to European healthcare professionals in accordance with the requirements of the European Medicines Agency (EMEA). We would encourage everyone to read the global update and MSWG guidance for detailed information on the global management plan.
IPA Statement Regarding the Management of Myozyme Supply – Advice to Patient Groups
IPA Statement Regarding the Management of Myozyme Supply – Advice to Pompe Patients
Guidance to the Pompe Community on the Management of Myozyme Supply
Myozyme Pompe Program Update – Global Version
Myozyme (2000L) Pompe Program Update – US Version
Myozyme Supply Frequently Asked Questions – compiled by the IPA (updated 18 January 2009)
In the document “Myozyme Supply Frequently Asked Questions” a lot of questions have already been answered. Should you have more questions after reading the documents: In the letter from the IPA chairman called “IPA Supply Letter-patients” you will find contact details.